Repurposed Poziotinib Offers New Hope for Some NSCLC Patients
Poizotinib, once abandoned as a general EGFR inhibitor, recently demonstrated tumor shrinkage in patients with an EGFR exon 20 insertion mutation.
Poliovirus Therapy May Provide a Double Attack on Cancer
An investigational therapy using modified poliovirus to attack cancer appears to unleash the body’s own capacity to fight malignancies by activating a newly identified inflammatory process.
Androgen Receptor Linked to Different Metastases in RCC
Researchers have discovered that androgen signaling can either stimulate or suppress tumor cell movement and invasion to different locations in the body in patients who have renal cell carcinoma.
Alectinib Approved as First-Line Therapy for ALK-Positive Metastatic NSCLC
The FDA approved alectinib as first-line therapy for ALK-positive non-small cell lung cancer based on results of the ALEX study, which showed significant improved PFS compared with crizotinib.
EZH2 Protein May be a Prognostic Marker for Localized Clear Cell RCC
Data from three independent cohorts suggest that high EZH2 expression may mean a higher risk of death for patients with clear cell renal cell carcinoma.
A New Method of Combating MAPK Inhibitor-Resistant Melanoma
Researchers have found that melanoma patients may benefit from a holiday from MAPK inhibitors while alternative therapies stave off emergence of resistant melanoma clones.
Pembrolizumab Demonstrates Increased Overall Survival in Metastatic NSCLC Patients
Data presented at the recent World Conference on Lung Cancer show that pembrolizumab improves overall survival in patients with metastatic non-small cell lung cancer whose tumors express high levels of PD-L1.
Tumor Infiltrating Lymphocytes May be Predictive in African-American Women with Triple-Negative Breast Cancer
For African-American women with triple-negative breast cancer, high levels of tumor infiltrating lymphocytes may mean a better prognosis.
Combating Breast Cancer Bone Metastases with Docetaxel-Encapsulated Nanotherapy
Researchers have developed nanoparticles that can carry targeted therapy to tumors with bone metastases, which may have particular benefit for breast cancer patients.
Radiation plus Immunotherapy May Benefit Some Patients with Metastatic NSCLC
Data presented at the ASTRO annual meeting demonstrate a benefit of radiation plus immunotherapy for patients with advanced disease, including stage IV NSCLC.